Previous 10 | Next 10 |
LOS ALTOS, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D.,...
LOS ALTOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that the peer-reviewed internatio...
2023-06-30 12:31:22 ET Gainers: Cyteir Therapeutics ( CYT ) +39% . Renalytix ( RNLX ) +39% . Rackspace Technology ( RXT ) +29% . Friedman Industries ( FRD ) +23% . Gracell Biotechnologies ( GRCL ) +23% . CytomX Therapeutics (...
2023-06-30 10:06:37 ET Gainers: CymaBay Therapeutics ( CBAY ) +36% . Cyteir Therapeutics ( CYT ) +34% . Renalytix ( RNLX ) +32% . CytomX Therapeutics ( CTMX ) +14% . Alvotech ( ALVO ) +13% . Losers: Unicycive Therapeutics ...
2023-06-30 08:41:13 ET Unicycive Therapeutics ( UNCY ) -26% regulatory update on Lanthanum Dioxycarbonate program . Paltalk ( PALT ) -21% . Root ( ROOT ) -18% on not receiving actionable offer . Eco Wave Power Global ( WAVE ) -17% . ...
LOS ALTOS, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today provided an update based on recent ...
LOS ALTOS, Calif., June 16, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced today that Company CEO, Shalabh Gupta, MD, has been invited to present at the Healthcare V...
ORLANDO, FL / ACCESSWIRE / June 9, 2023 / RedChip Companies will air new interviews with Unicycive Therapeutics, Inc. (Nasdaq:UNCY) and Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) on The RedChip Money Report® on Bloomberg TV, this Saturday, June 10, at 7 p.m. Eastern Time (ET). Bloomberg ...
Closed on previously announced transformational fundraising that included $30 million financing upfront with up to an additional $100 million tied to the satisfaction of milestones Continued progress with plan to file New Drug Application with the U.S. Food and Drug Administration in Q3...
LOS ALTOS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, today announced that two datasets highlighting the safety and suggestive efficacy of UNI-494 i...
News, Short Squeeze, Breakout and More Instantly...
Unicycive Therapeutics Inc. Company Name:
UNCY Stock Symbol:
NASDAQ Market:
Unicycive Therapeutics Inc. Website:
LOS ALTOS, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced it was included in the Ru...
– Successfully Established Favorable Tolerability and Safety of OLC – – New Drug Application (NDA) Submission Anticipated in Q3 2024 – – Webcast and Conference Call Today at 8:30 A.M. ET – LOS ALTOS, Calif., June 25, 2024 (GLOBE NE...
– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor – – Oral UNI-494 Shows Promise in a Preclinical Model as a Potential Candidate for Prevention of Delayed Graft Function Related to Acute Kidney Injury...